Amicus Therapeutics (LTS:0HF9) Dividends per Share : $0.00 (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amicus Therapeutics Dividends per Share?

Amicus Therapeutics's dividends per share for the three months ended in Jun. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Jun. 2024 was 0.00. As of today, Amicus Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Amicus Therapeutics Dividends per Share Historical Data

The historical data trend for Amicus Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Dividends per Share Chart

Amicus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Amicus Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Amicus Therapeutics's Dividends per Share

For the Biotechnology subindustry, Amicus Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's Dividend Yield % falls into.

Amicus Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Amicus Therapeutics (LTS:0HF9) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Amicus Therapeutics's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	EPS without NRI (Q: Jun. 2024 )
	=	0	/	0.06
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Amicus Therapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (LTS:0HF9) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

FOLD:USA AM6:Germany AM6:Germany

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines